

US PATENT & TRADEMARK OFFICE

PATENT APPLICATION FULL TEXT AND IMAGE DATABASE

[Help](#)
[Home](#)
[Boolean](#)
[Manual](#)
[Number](#)
[PTDLs](#)

[Next List](#)
[Bottom](#)
[View Shopping Cart](#)

Searching PGPUB Production Database March 15th - September 30th 2001...

Results of Search in PGPUB Production Database March 15th - September 30th 2001 for:
AANM/"IMMUNOMEDICS INC": 230 applications.

Hits 1 through 50 out of 230

Next 50 Hits

Jump To

Refine Search

AANM/"IMMUNOMEDICS INC"

PUB. APP. NO.	Title
1	20220054648 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
2	20210395385 EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
3	20210393617 THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
4	20210346511 IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE
5	20210275682 NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES
6	20210093730 BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY
7	20210069343 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
8	20210046185 DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
9	20200316054 DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
10	20200276325 Immunoconjugates with an Intracellularly-Cleavable Linkage
11	20200246481 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
12	20200121805 Immunoconjugates with an Intracellularly-Cleavable Linkage
13	20200085968 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
14	20190381032 THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
15	20190369103 ISOLATION, DETECTION, DIAGNOSIS AND/OR CHARACTERIZATION OF CIRCULATING TROP-2-POSITIVE CANCER CELLS
16	20190248917 COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
17	20190209703 COMBINING ANTI-HLA-DR OR ANTI-TROP-2 ANTIBODIES WITH MICROTUBULE INHIBITORS, PARP INHIBITORS, BRUTON KINASE INHIBITORS OR PHOSPHOINOSITIDE 3-KINASE INHIBITORS SIGNIFICANTLY IMPROVES THERAPEUTIC OUTCOME IN CANCER

- 18 [20190194318](#) [Immunoconjugates with an Intracellularly-Cleavable Linkage](#)
- 19 [20190177427](#) [EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS](#)
- 20 [20190167805](#) [Immunoconjugates with an Intracellularly-Cleavable Linkage](#)
- 21 [20190083621](#) [RS7 Antibodies](#)
- 22 [20190083487](#) [EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 \(hL243-CL2A-SN-38\) IN HLA-DR POSITIVE CANCERS](#)
- 23 [20190083451](#) [SYNERGISTIC EFFECT OF ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE IN COMBINATION THERAPY FOR TRIPLE-NEGATIVE BREAST CANCER WHEN USED WITH MICROTUBULE INHIBITORS OR PARP INHIBITORS](#)
- 24 [20190071503](#) [Humanized Anti-HLA-DR Antibodies](#)
- 25 [20190070308](#) [ANTIBODY-DRUG CONJUGATES AND USES THEREOF](#)
- 26 [20190030175](#) [ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER](#)
- 27 [20190022226](#) [Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity](#)
- 28 [20190015405](#) [DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY](#)
- 29 [20180327495](#) [COMBINATION THERAPY WITH ANTI-HLA-DR ANTIBODIES AND KINASE INHIBITORS IN HEMATOPOIETIC CANCERS](#)
- 30 [20180318439](#) [Immunoconjugates with an Intracellularly-Cleavable Linkage](#)
- 31 [20180298089](#) [Chimeric and Humanized Anti-Histone Antibodies](#)
- 32 [20180296689](#) [NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES](#)
- 33 [20180280532](#) [SUBCUTANEOUS ADMINISTRATION OF ANTIBODY-DRUG CONJUGATES FOR CANCER THERAPY](#)
- 34 [20180271992](#) [TREATMENT OF HIGH TROP-2 EXPRESSING TRIPLE NEGATIVE BREAST CANCER \(TNBC\) WITH SACITUZUMAB GOVITECAN \(IMMU-132\) OVERCOMES HOMOLOGOUS RECOMBINATION REPAIR \(HRR\) RESCUE MEDIATED BY RAD51](#)
- 35 [20180250406](#) [RS7 Antibodies](#)
- 36 [20180185351](#) [THERAPY OF SMALL-CELL LUNG CANCER \(SCLC\) WITH A TOPOISOMERASE-I INHIBITING ANTIBODY-DRUG CONJUGATE \(ADC\) TARGETING TROP-2](#)
- 37 [20180171003](#) [Chimeric and Humanized Anti-Histone Antibodies](#)
- 38 [20180162945](#) [SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES](#)
- 39 [20180161440](#) [ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER](#)
- 40 [20180149657](#) [ISOLATION, DETECTION, DIAGNOSIS AND/OR CHARACTERIZATION OF CIRCULATING TROP-2-POSITIVE CANCER CELLS](#)
- 41 [20180133322](#) [RS7 Antibodies](#)
- 42 [20180110772](#) [THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN \(IMMU-132\)](#)
- 43 [20180085469](#) [ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER](#)
- 44 [20180057574](#) [ANTI-HISTONE THERAPY IN ACUTE KIDNEY INJURY](#)
- 45 [20180051085](#) [NOVEL ANTI-PD-1 CHECKPOINT INHIBITOR ANTIBODIES THAT BLOCK BINDING OF PD-L1 TO PD-1](#)
- 46 [20180022796](#) [Chimeric and Humanized Anti-Histone Antibodies](#)
- 47 [20170360770](#) [EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 \(hL243-CL2A-SN-38\) IN HLA-DR POSITIVE CANCERS](#)
- 48 [20170334996](#) [FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES](#)
- 49 [20170326238](#) [CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS](#)

50 [20170320952](#) [METHODS OF TREATING CANCER WITH ANTIBODIES THAT TARGET THE INSULIN-LIKE GROWTH FACTOR TYPE I RECEPTOR \(IGF-1R\)](#)

[Next List](#)[Top](#)[View Shopping Cart](#)

[Help](#)[Home](#)[Boolean](#)[Manual](#)[Number](#)[PTDLs](#)